1.Adverse effects of oxcarbazepine.
Chinese Journal of Contemporary Pediatrics 2015;17(4):414-419
Oxcarbazepine is a new antiepileptic drug. The results of clinical trials suggest that oxcarbazepine is well tolerated and has less drug interactions. It is being used more and more widely in clinical practice, but its adverse effects should not be ignored. The most common adverse effects of oxcarbazepine are usually related to the central nervous system and digestive system, including fatigue, drowsiness, diplopia, dizziness, nausea and vomit. The common skin adverse reaction is rash. Long-term use of oxcarbazepine may also cause hyponatremia. This article reviews the literature from China and overseas about the adverse effets of oxcarbazepine over the last 10 years in order to find information about rational clinical use of oxcarbazepine.
Anticonvulsants
;
adverse effects
;
Carbamazepine
;
adverse effects
;
analogs & derivatives
;
Exanthema
;
chemically induced
;
Humans
;
Hyponatremia
;
chemically induced
2.Great attention should be paid to the adverse drug reactions associated with the use of molecular targeted anticancer drugs.
Zheng-tang CHEN ; Yu-zhong DUAN ; Jian-cheng XU
Chinese Journal of Oncology 2009;31(12):881-884
Antineoplastic Agents
;
adverse effects
;
therapeutic use
;
Diarrhea
;
chemically induced
;
Drug Delivery Systems
;
methods
;
Exanthema
;
chemically induced
;
Humans
;
Leukopenia
;
chemically induced
;
Lung Diseases, Interstitial
;
chemically induced
;
Myocardial Infarction
;
chemically induced
;
Neoplasms
;
drug therapy
;
Tumor Lysis Syndrome
;
etiology
3.Prolonged pruritic rash following influenza A (H1N1) vaccination.
Singapore medical journal 2013;54(5):e117-9
In Singapore, the approved influenza A (H1N1) vaccines are Panvax® and Pandemrix®. An estimated 425,000 doses of Panvax and less than 100 doses of Pandemrix had been distributed in Singapore from November 2009 to February 2010. Reviews on the H1N1 vaccine have concluded that it has a safety profile similar to that of seasonal influenza vaccines. From the time the H1N1 vaccination was implemented in Singapore on November 3, 2009, up to October 11, 2010, the Health Sciences Authority had received 173 adverse event reports from healthcare professionals. We report a case of prolonged illness after H1N1 vaccination.
Adult
;
Exanthema
;
chemically induced
;
diagnosis
;
Female
;
Humans
;
Influenza A Virus, H1N1 Subtype
;
Influenza Vaccines
;
adverse effects
;
Prednisolone
;
therapeutic use
;
Pruritus
;
chemically induced
;
diagnosis
;
Singapore
;
Treatment Outcome
;
Vaccination
;
adverse effects
4.Adverse reactions of methimazole in children with hyperthyroidism.
Chinese Journal of Contemporary Pediatrics 2022;24(11):1252-1258
OBJECTIVES:
To investigate the incidence rate of adverse reactions of methimazole in children with hyperthyroidism.
METHODS:
A retrospective analysis was performed on the medical data of 304 children with hyperthyroidism who were hospitalized in Shengjing Hospital of China Medical University from January 2015 to May 2021. The incidence rate of methimazole-related adverse reactions was analyzed. The risk factors for common adverse reactions were evaluated.
RESULTS:
Among the 304 children, 87 (28.6%) experienced adverse reactions, among whom there were 20 boys (23%) and 67 girls (77%). Common adverse reactions included neutropenia (12.8%), rash (11.8%), elevated alanine aminotransferase (9.5%), and joint pain (3.0%), and some children experienced multiple adverse reactions simultaneously or intermittently. Neutropenia often occurred within 3 months after administration (25/39, 64%), elevated alanine aminotransferase often occurred within 1 month after administration (17/29, 59%), and rash often occurred within 3 months after administration (30/36, 83%). Most of the above adverse reactions returned to normal after symptomatic treatment. The multivariate logistic regression analysis showed that younger age and lower absolute neutrophil count before treatment were risk factors for neutropenia after methimazole treatment (P<0.05).
CONCLUSIONS
The adverse reactions of methimazole are common in children with hyperthyroidism, and most adverse reactions occur within 3 months after administration and can be relieved after symptomatic treatment. Children with a younger age or a lower baseline absolute neutrophil count may have a higher risk of neutropenia.
Male
;
Child
;
Female
;
Humans
;
Methimazole/adverse effects*
;
Antithyroid Agents/adverse effects*
;
Retrospective Studies
;
Alanine Transaminase
;
Hyperthyroidism/chemically induced*
;
Neutropenia/chemically induced*
;
Exanthema
5.Interpretation of contemporary positioning of traditional Chinese medicine injections and analysis of key problems.
Fei GAO ; Jing LENG ; Chao-Mei FU ; Jin-Ming ZHANG ; Wan LIAO ; Hui-Ling HU ; Yao HE ; Yan-Xiong GAN ; Li HAO
China Journal of Chinese Materia Medica 2014;39(17):3416-3419
According to the current situations and development of (TCMIs), the author of the article reveals the scientific connotation of TCMIs in theory, preparations and clinic application, and points out that TCMIs are an innovative and breakthrough of conventional dosage forms of traditional Chinese medicines, the combination of traditional theory and modern technology as well as a type of modern dosage form with the characteristics of traditional Chinese medicines, which conforms to the principle of including the essence and excluding the wastes for traditional Chinese medicine preparations, meets the demands for quick-acting of traditional Chinese medicines and guides one of the development orientation of traditional Chinese medicines. In the meantime, an analysis was also made on key issues, such as adverse reactions of TCMIs, modern clinical application, special drug delivery route and diversity of components and ingredients.
Drug Delivery Systems
;
methods
;
Drugs, Chinese Herbal
;
administration & dosage
;
adverse effects
;
Exanthema
;
chemically induced
;
Humans
;
Injections
;
adverse effects
;
Medicine, Chinese Traditional
;
adverse effects
;
methods
;
trends
;
Nausea
;
chemically induced
;
Product Surveillance, Postmarketing
;
methods
;
statistics & numerical data
;
Vomiting
;
chemically induced
6.Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Lan-Fang LI ; Hua-Qing WANG ; Xian-Ming LIU ; Hui-Lai ZHANG ; Li-Hua QIU ; Zheng-Zi QIAN ; Wei LI
Chinese Journal of Oncology 2011;33(8):626-628
OBJECTIVETo evaluate the role of nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
METHODSThe clinical data of 37 NSCLC patients who received nimotuzumab in combination with chemotherapy in Tianjin Medical University Cancer Hospital from January 2009 to October 2010 were retrospectively reviewed. Of the thirty-seven patients, 12 patients were in stage III B, 25 patients in stage IV. Twenty-four patients recived platinum-based chemotherapy in combination with nimotuzumab, 13 patients recived nonplatinum-based chemotherapy in combination with nimotuzumab. Ten patients received nimotuzumab in combination with chemotherapy as first-line regimen, 23 patients as second-line regimen, 4 patients as third-line regimen.
RESULTSOf the 37 advanced NSCLC patients who received nimotuzumab in combination with chemotherapy, the total number of chemotherapy were 137 cycles, the mean number was 3.7 cycles. One patient had complete remission (CR), 9 patients had partial remission (PR), 16 cases had stable disease (SD), and 11 patients had progressive disease (PD). The response rate (RR) was 27% and clinical benefit rate (CBR) was 70.3%. The main side effects were bone marrow suppression and gastrointestinal reactions. Grade I acneiform rash was found in one patient.
CONCLUSIONThe regimen of nimotuzumab in combination with chemotherapy can improve the response rate and was well tolerated in patients with advanced non-small cell lung cancer.
Adult ; Aged ; Agranulocytosis ; chemically induced ; Antibodies, Monoclonal, Humanized ; adverse effects ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; pathology ; Exanthema ; chemically induced ; Female ; Humans ; Lung Neoplasms ; drug therapy ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Platinum ; administration & dosage ; Remission Induction ; Retrospective Studies ; Thrombocytopenia ; chemically induced ; Vomiting ; chemically induced
7.Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs.
Lindi JIANG ; Naiqing ZHAO ; Liqing NI
Chinese Journal of Epidemiology 2002;23(3):213-217
OBJECTIVETo evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA).
METHODEight hundred and sixty-four RA patients were studied in a retrospective program.
RESULTSUpper abdominal discomfort was most commonly seen when using second-line drugs. Rash was often associated with D-penicillamine (20.6%) and Sinomenium therapy (13.7%). Methotrexate (MTX) was uniquely characterized by substantial upper GI toxicity (32.2%) and Tripterygium wilfordii Hook. f. (TWH) (14.4%) by menstrual abnormality. Sulfasalazine users reported adverse events including upper abdominal trouble (39.0%), nausea (7.3%) and anorexia (7.3%) while the risk of GI malaise was greater. Patients taking hydroxychloroquine complained of blurred vision (19.6%) but no one went blind. Toxic side effects seemed to be the most common reasons for stoppages, and the patients taking MTX had the lowest discontinuation rate. Combination of D-penicillamine and Methotrexate did not increase the incidence of adverse events.
CONCLUSIONSKnowledge on these different patterns of toxicity provided choices in the selection of second line agents for particular RA patients. However, long-term monitor are required when drugs are being used.
Adult ; Anorexia ; chemically induced ; Antirheumatic Agents ; adverse effects ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Exanthema ; chemically induced ; Female ; Gastrointestinal Diseases ; chemically induced ; Humans ; Hydroxychloroquine ; adverse effects ; therapeutic use ; Male ; Methotrexate ; adverse effects ; therapeutic use ; Middle Aged ; Nausea ; chemically induced ; Penicillamine ; adverse effects ; therapeutic use ; Phytotherapy ; Plant Preparations ; adverse effects ; therapeutic use ; Retrospective Studies ; Sinomenium ; Sulfasalazine ; adverse effects ; therapeutic use
8.Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
Byung Ha CHUNG ; Jian HUANG ; Zhang-Qun YE ; Da-Lin HE ; Hirotsugu UEMURA ; Gaku ARAI ; Choung Soo KIM ; Yuan-Yuan ZHANG ; Yusoke KOROKI ; SuYeon JEONG ; Suneel MUNDLE ; Spyros TRIANTOS ; Sharon MCCARTHY ; Kim N CHI ; Ding-Wei YE
Asian Journal of Andrology 2022;24(2):161-166
Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial was conducted at 260 sites in 23 countries. This subgroup analysis included patients enrolled in 62 participating centers in China, Japan, and Korea. Radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and PSA changes from baseline were compared between groups in the East Asian population. The intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups, respectively. The 24-month radiographic PFS rates were 76.1% and 52.3% in the apalutamide and placebo groups, respectively (apalutamide vs placebo: hazard ratio [HR] = 0.506; 95% confidence interval [CI], 0.302-0.849; P = 0.009). Median time to PSA progression was more favorable with apalutamide than placebo (HR = 0.210; 95% CI, 0.124-0.357; P < 0.001). Median maximum percentages of PSA decline from baseline were 99.0% and 73.9% in the apalutamide and placebo groups, respectively. The most common adverse event (AE) was rash in the apalutamide group, with a higher rate than that in the placebo group (37.3% vs 9.1%). The most common grade 3 or 4 AEs were rash (12 [10.9%]) and hypertension (12 [10.9%]) for apalutamide. The efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results.
Androgen Antagonists/adverse effects*
;
Exanthema/chemically induced*
;
Far East
;
Humans
;
Male
;
Prostate-Specific Antigen
;
Prostatic Neoplasms, Castration-Resistant/pathology*
;
Thiohydantoins/adverse effects*
9.Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy.
Yan SUN ; Yi-long WU ; Long-yun LI ; Mei-lin LIAO ; Guo-liang JIANG ; Edward S KIM ; Jean-yves DOUILLARD ; Tsveta MILENKOVA
Chinese Journal of Oncology 2011;33(5):377-380
OBJECTIVETo compare the efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy.
METHODSWe retrospectively reviewed 222 Chinese NSCLC patients in the subgroup of INTEREST (gefitinib versus docetaxel in previously treated non-small cell lung cancer) study. Survival analysis was evaluated by Kaplan-Meier method, and Functional Assessment of Cancer Therapy-Lung (FACT-L) was used to compare the quality of life between gefitinib group and docetaxel group.
RESULTSA total of 222 patients were analyzed in this subgroup study. 107 patients were treated with gefitinib, and 115 patients treated with docetaxel. There were all balanced between the two groups in terms of sex, age, staging and pathology in patient characteristics. The median overall survival in the two groups was similar (11 months in the gefitinib group vs. 14.0 months in the docetaxel group, P = 0.783). The progression-free survival (PFS) was also similar between the two groups (median PFS: 3.4 months in gefitinib group vs. 3.8 months in docetaxel group, P = 0.214). The response rate in gefitinib group was significantly higher than that in the docetaxel group (21.9% vs. 9.1%, P = 0.016).
CONCLUSIONThe efficacy of gefitinib is similar with that of docetaxel in pretreated patients with locally advanced or metastatic NSCLC, however, gefitinib is more favorable in the tolerance and quality of life improvement.
Adult ; Antineoplastic Agents ; adverse effects ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; pathology ; Diarrhea ; chemically induced ; Disease-Free Survival ; Exanthema ; chemically induced ; Female ; Humans ; Lung Neoplasms ; drug therapy ; pathology ; Male ; Neoplasm Staging ; Neutropenia ; chemically induced ; Platinum ; therapeutic use ; Quality of Life ; Quinazolines ; adverse effects ; therapeutic use ; Randomized Controlled Trials as Topic ; Remission Induction ; Retrospective Studies ; Survival Rate ; Taxoids ; adverse effects ; therapeutic use
10.A Case of Mexiletine-induced Hypersensitivity Syndrome Presenting as Eosinophilic Pneumonia.
Sang Pyo LEE ; Sang Heon KIM ; Tae Hyung KIM ; Jang Won SOHN ; Dong Ho SHIN ; Sung Soo PARK ; Ho Joo YOON
Journal of Korean Medical Science 2010;25(1):148-151
An 82-yr-old man was presented with fever and cough accompanied by generalized erythematous rash. He had taken mexiletine for 5 months, as he had been diagnosed with dilated cardiomyopathy and ventricular arrhythmia. Laboratory studies showed peripheral blood eosinophilia and elevated liver transaminase levels. Chest radiographs showed multiple nodular consolidations in both lungs. Biopsies of the lung and skin lesions revealed eosinophilic infiltration. After a thorough review of his medication history, mexiletine was suspected as the etiologic agent. After discontinuing the mexiletine and starting oral prednisolone, the patient improved, and the skin and lung lesions disappeared. Subsequently, mexiletine was confirmed as the causative agent based on a positive patch test. Drug-induced hypersensitivity syndrome is a severe adverse reaction to drugs and results from treatment with anticonvulsants, allopurinol, sulfonamides, and many other drugs. Several cases of mexiletine-induced hypersensitivity syndrome have been reported in older Japanese males with manifestation of fever, rash, peripheral blood eosinophilia, liver dysfunction without other organ involvement. Here, we report a case of mexiletine-induced hypersensitivity syndrome which presented as eosinophilic pneumonia in a Korean male.
Aged, 80 and over
;
Anti-Arrhythmia Agents/*adverse effects
;
Arrhythmias, Cardiac/drug therapy
;
Cardiomyopathy, Dilated/drug therapy
;
Drug Hypersensitivity/*diagnosis/etiology
;
Exanthema/pathology
;
Humans
;
Lung/pathology/radiography
;
Male
;
Mexiletine/*adverse effects
;
Pulmonary Eosinophilia/*chemically induced/*diagnosis
;
Syndrome
;
Tomography, X-Ray Computed